Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,217,200 papers from all fields of science
Search
Sign In
Create Free Account
Myopathies, Nemaline
Known as:
Myopathy, Rod Body
, Nemaline Rod Disease
, Myopathy, Rod
Expand
A group of inherited congenital myopathic conditions characterized clinically by weakness, hypotonia, and prominent hypoplasia of proximal muscles…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
26 relations
Narrower (14)
Adult Onset Nemaline Myopathy
Cardioneuromyopathy with Hyaline Masses and Nemaline Rods
Intranuclear Rod Myopathy
Myopathy, Actin, Congenital, with Excess of Thin Myofilaments
Expand
Benign congenital hypotonia
Central Core Myopathy (disorder)
Congenital muscular dystrophy (disorder)
Floppy infant syndrome
Expand
Broader (1)
Myopathy
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Nemaline myopathies: a current view
C. Sewry
,
J. Laitila
,
C. Wallgren‐Pettersson
Journal of Muscle Research and Cell Motility
2019
Corpus ID: 195246536
Nemaline myopathies are a heterogenous group of congenital myopathies caused by de novo, dominantly or recessively inherited…
Expand
Review
2013
Review
2013
International Workshop : Inclusion Body Myositis , 2 – 4 December 2011 , Naarden , The Netherlands
M. Rose
2013
Corpus ID: 31299409
The 188th ENMC workshop titled “Inclusion Body Myositis” was held in Naarden, The Netherlands, 2–4 December 2011. The workshop…
Expand
Review
2010
Review
2010
High‐throughput screening and small animal models, where are we?
Jean Giacomotto
,
L. Ségalat
British Journal of Pharmacology
2010
Corpus ID: 17150919
Current high‐throughput screening methods for drug discovery rely on the existence of targets. Moreover, most of the hits…
Expand
Review
2010
Review
2010
Centronuclear myopathies: A widening concept
N. Romero
Neuromuscular Disorders
2010
Corpus ID: 5825136
Highly Cited
2009
Highly Cited
2009
Thin filament length dysregulation contributes to muscle weakness in nemaline myopathy patients with nebulin deficiency.
C. Ottenheijm
,
C. Witt
,
G. Stienen
,
S. Labeit
,
A. Beggs
,
H. Granzier
Human Molecular Genetics
2009
Corpus ID: 15027102
Nemaline myopathy (NM) is the most common non-dystrophic congenital myopathy. Clinically the most important feature of NM is…
Expand
Review
2005
Review
2005
Sporadic late onset nemaline myopathy
N. Chahin
,
D. Selcen
,
A. Engel
Neurology
2005
Corpus ID: 23334154
Objective: To review the clinicopathologic features and outcome of sporadic late onset nemaline myopathy (SLONM). Background: Non…
Expand
Review
2001
Review
2001
Nemaline myopathy: A clinical study of 143 cases
M. Ryan
,
C. Schnell
,
+6 authors
K. North
Annals of Neurology
2001
Corpus ID: 8648543
We report 143 Australian and North American cases of primary nemaline myopathy. As classified by the European Neuromuscular…
Expand
Highly Cited
2000
Highly Cited
2000
The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK.
F. Duprat
,
F. Lesage
,
A. Patel
,
M. Fink
,
G. Romey
,
M. Lazdunski
Molecular Pharmacology
2000
Corpus ID: 27376727
Riluzole (RP 54274) is a potent neuroprotective agent with anticonvulsant, sedative, and anti-ischemic properties. It is…
Expand
Highly Cited
1998
Highly Cited
1998
The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism
G. Rozas
,
E. López-Martín
,
M. Guerra
,
J. Labandeira-Garcia
Journal of Neuroscience Methods
1998
Corpus ID: 21916249
Highly Cited
1995
Highly Cited
1995
Reliability of Spike Timing in Neocortical Neurons
O. Prospero-Garcia
,
G. Siuzdak
,
S. Henriksen
,
D. Boger
1995
Corpus ID: 16173898
screen of the microscope. Between 150 to 300 nerve fibers were analyzed per cross section. 13. C. F. Eldridge, M. Bartlett, R. P…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE